# Sac-TMT Combined With Fruquintinib as Second-Line Treatment in Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

> **NCT07689292** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 45 (estimated)

## Conditions studied

- Gastric Adenocarcinoma
- Gastroesophageal Junction (GEJ) Adenocarcinoma
- Gastro-esophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Sacituzumab Tirumotecan + Fruquintinib

## Key facts

- **NCT ID:** NCT07689292
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-31
- **Primary completion:** 2027-08-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-07-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07689292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07689292, "Sac-TMT Combined With Fruquintinib as Second-Line Treatment in Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07689292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*